iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Tables)

6 Months Ended

Dec. 31, 2022


	Three Months Ended				Six Months Ended
	December 31,				December 31,
	2022		2021		2022		2021
Basic and diluted numerator:

Net loss attributable to iBio, Inc. from continuing operations	$	(10,563)	$	(7,191)	$	(18,100)	$	(12,379)
Preferred stock dividends – iBio CMO Preferred Tracking Stock		—		(22)		—		(88)
Net loss available to iBio, Inc. stockholders from continuing operations	$	(10,563)	$	(7,213)	$	(18,100)	$	(12,467)

Net loss available to iBio, Inc. stockholders from discontinued operations	$	(22,990)	$	(4,729)	$	(33,583)	$	(8,480)

Net loss available to iBio, Inc. stockholders - total	$	(33,553)	$	(11,942)	$	(51,683)	$	(20,947)

Basic and diluted denominator:

Weighted-average common shares outstanding		9,807		8,715		9,324		8,715

Per share amount - continuing operations	$	(1.08)	$	(0.83)	$	(1.94)	$	(1.43)
Per share amount - discontinued operations	$	(2.34)	$	(0.54)	$	(3.60)	$	(0.97)
Per share amount - total	$	(3.42)	$	(1.37)	$	(5.54)	$	(2.40)


	December 31,
	2022	2021

	(in thousands)
Stock options	708	598
Restricted stock units	231	31
Warrants	7,994	52
Shares excluded from the calculation of diluted loss per share	8,933	681